紫斑病治療の世界市場レポート2025年

紫斑病治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.7％で21億2,000万米ドルに成長します。今後の市場開拓は、生物学的療法の開発、遺伝子スクリーニング需要の高まり、早期診断のための遠隔医療への依存の高まり、希少疾患治療に対する規制上の優遇措置、カスタマイズされた治療アプローチへのシフトによって促進されます。予測期間中に予想される主な動向には、遺伝子ベースの治療法の進歩、細胞治療の革新、高精度ドラッグデリバリー技術、ウェアラブル診断ツールの採用、ナノテクノロジーに基づく医療の進歩などがあります。

自己免疫疾患の有病率の増加は、紫斑病治療市場の拡大を促進すると予想されます。自己免疫疾患は、身体の免疫系が自身の健康な細胞や組織を、細菌やウイルスなどの有害な侵入者であると誤って攻撃することで発生します。多くの場合、環境的誘因が炎症や分子模倣を促進することによってこの一因となり、免疫系が体自身の組織を攻撃するようになり、自己免疫疾患のリスクが高まる。紫斑病の治療は、過剰な免疫反応を抑制し、血小板産生を促進し、血管の炎症を抑えることで、自己免疫疾患の管理に重要な役割を果たします。これにより、免疫性血小板減少性紫斑病（ITP）のような自己免疫関連の紫斑病でよくみられる、あざ、出血、血小板数の減少などの症状を抑えることができます。例えば、2023年3月、英国政府部門であるOffice for Health Improvement &Disparitiesが発表した報告書によると、2022年には16歳以上の17.6％が長期の筋骨格系（MSK）疾患を有すると報告し、2021年の17.0％から増加しています。このように、自己免疫疾患の有病率の上昇が紫斑病治療市場の成長を促進しています。

個別化医療に対する需要の高まりも紫斑病治療市場を押し上げると予想されます。個別化医療とは、遺伝的体質、環境要因、ライフスタイルに基づいて、個々の患者に合わせた治療や診療を行うことです。この需要は、ゲノミクスとバイオテクノロジーの進歩により、個々の遺伝子プロファイルに合わせたより正確で効果的な治療が可能となり、最終的に患者の転帰を改善し、副作用を最小限に抑えることができるようになりました。紫斑病の文脈では、個別化医療は遺伝子や免疫系のデータを用いて治療をカスタマイズすることで、患者独自の生物学的反応に基づいて治療効果を改善し、副作用を軽減します。例えば、米国を拠点とする専門家会員組織である個別化医療連合によれば、2022年には、新たに承認された12の個別化医薬品が、その年に承認された全新治療法の約34％を占め、以前からの大幅な伸びを反映しています。したがって、個別化医療への関心の高まりが紫斑病治療市場の拡大に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の紫斑病治療：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の紫斑病治療市場：成長率分析
• 世界の紫斑病治療市場の実績：規模と成長, 2019-2024
• 世界の紫斑病治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の紫斑病治療：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の紫斑病治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非血小板減少性紫斑病
• 血小板減少性紫斑病
• アレルギー性紫斑病
• 世界の紫斑病治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所治療
• 経口薬
• 硝子体内注射
• レーザー療法
• 光線力学療法
• 世界の紫斑病治療市場ケース別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性
• 慢性
• 世界の紫斑病治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の紫斑病治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他のエンドユーザー
• 世界の紫斑病治療市場非血小板減少性紫斑病の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 特発性紫斑病
• 老人性紫斑病
• 紫斑血管異常
• 世界の紫斑病治療市場血小板減少性紫斑病の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫血小板減少性紫斑病（ITP）
• 薬剤誘発性血小板減少性紫斑病
• 二次性血小板減少性紫斑病
• 世界の紫斑病治療市場アレルギー性紫斑病の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬剤誘発性アレルギー性紫斑病
• 食物誘発性アレルギー性紫斑病
• 感染関連アレルギー性紫斑病

第7章 地域別・国別分析

• 世界の紫斑病治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の紫斑病治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 紫斑病治療市場：競合情勢
• 紫斑病治療市場：企業プロファイル
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• CSL Limited
• Intas Pharmaceuticals Ltd.
• Biogen Inc.
• Chugai Pharmaceutical Co Ltd.
• Sun Pharmaceutical Industries Limited
• Octapharma AG
• Grifols S.A.
• GC Pharma
• Emergent BioSolutions Inc.
• Kissei Pharmaceutical Co Ltd.
• Ablynx N.V.
• Shire plc
• Lee's Pharmaceutical Holdings Limited
• Omeros Corporation
• KM Biologics Co Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 紫斑病治療市場2029：新たな機会を提供する国
• 紫斑病治療市場2029：新たな機会を提供するセグメント
• 紫斑病治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Purpura treatment refers to the medical care and management of purpura, which are purple-colored spots or patches on the skin caused by small blood vessels leaking under the skin. Purpura treatment is utilized by healthcare providers to manage symptoms and address underlying conditions such as platelet disorders, infections, or autoimmune diseases that cause bleeding under the skin.

The main types of purpura treatment include non-thrombocytopenic purpura, thrombocytopenic purpura, and allergic purpura. Non-thrombocytopenic purpura is characterized by bleeding under the skin, resulting in red or purple discoloration (purpura). These conditions are managed through different treatment approaches, such as topical therapies, oral medications, intravitreal injections, laser treatments, and photodynamic therapy. Purpura may present as either acute or chronic cases and is distributed through several channels, including hospital pharmacies, online pharmacies, and retail pharmacies. The treatments are utilized by various end users, such as hospitals, clinics, and other healthcare facilities.

The purpura treatment market research report is one of a series of new reports from The Business Research Company that provides purpura treatment market statistics, including purpura treatment industry global market size, regional shares, competitors with a purpura treatment market share, purpura treatment market segments, market trends and opportunities, and any further data you may need to thrive in the purpura treatment industry. This purpura treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The purpura treatment market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The historical growth has been driven by the introduction of new therapeutic options, increased use of corticosteroids, growth in clinical research initiatives, rising healthcare expenditure, and improvements in hospital facilities.

The purpura treatment market size is expected to see strong growth in the next few years. It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. Future market expansion will be fueled by the development of biologic therapies, rising demand for genetic screening, increased reliance on telehealth for early diagnosis, regulatory incentives for rare disease treatments, and a shift toward customized treatment approaches. Key trends anticipated during the forecast period include progress in gene-based therapies, innovations in cell therapy, precision drug delivery technologies, adoption of wearable diagnostic tools, and advancements in nanotechnology-based medicine.

The growing prevalence of autoimmune diseases is expected to drive the expansion of the purpura treatment market. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells and tissues, believing they are harmful invaders such as bacteria or viruses. Environmental triggers often contribute to this by promoting inflammation or molecular mimicry, which leads the immune system to attack the body's own tissues and increases the risk of autoimmune diseases. Treatments for purpura play a crucial role in managing autoimmune diseases by suppressing the overactive immune response, enhancing platelet production, and reducing inflammation in blood vessels. This helps control symptoms like bruising, bleeding, and low platelet counts, which are commonly seen in autoimmune-related purpura such as immune thrombocytopenic purpura (ITP). For example, in March 2023, a report published by the Office for Health Improvement & Disparities, a UK government department, stated that in 2022, 17.6% of individuals aged 16 and above reported having a long-term musculoskeletal (MSK) condition, an increase from 17.0% in 2021. Thus, the rise in autoimmune disease prevalence is fueling the growth of the purpura treatment market.

The increasing demand for personalized medicine is also expected to boost the purpura treatment market. Personalized medicine involves tailoring medical treatments and practices to individual patients based on their genetic makeup, environmental factors, and lifestyle. This demand is being driven by advances in genomics and biotechnology, which allow for more precise and effective treatments tailored to individual genetic profiles, ultimately improving patient outcomes and minimizing side effects. In the context of purpura, personalized medicine uses genetic and immune system data to customize therapies, thereby improving treatment effectiveness and reducing adverse effects for patients based on their unique biological responses. For instance, according to the Personalized Medicine Coalition, a U.S.-based professional membership organization, in 2022, 12 newly approved personalized medicines accounted for approximately 34% of all new therapies approved that year, reflecting significant growth from previous years. Therefore, the growing interest in personalized medicine is contributing to the expansion of the purpura treatment market.

Leading companies in the purpura treatment market are prioritizing advancements in therapeutic options such as oral spleen tyrosine kinase (SYK) inhibitors to enhance treatment outcomes. These oral SYK inhibitors are medications that block the SYK enzyme, which plays a key role in the immune system's signaling processes. For example, in April 2023, Kissei Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, introduced TAVALISSE tablets (100 mg and 150 mg) in Japan as an oral treatment for adult patients with chronic idiopathic thrombocytopenic purpura (ITP). TAVALISSE (fostamatinib sodium hydrate) works by inhibiting the destruction of platelets by macrophages, thus improving bleeding symptoms in chronic ITP patients. It was approved in Japan following a Phase 3 clinical trial (R788-1301), where 36% of patients achieved a stable platelet response compared to 0% in the placebo group, demonstrating its effectiveness as a new treatment option.

Major players in the purpura treatment market are Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., CSL Limited, Intas Pharmaceuticals Ltd., Biogen Inc., Chugai Pharmaceutical Co Ltd., Sun Pharmaceutical Industries Limited, Octapharma AG, Grifols S.A., GC Pharma, Emergent BioSolutions Inc., Kissei Pharmaceutical Co Ltd., Ablynx N.V., Shire plc, Lee's Pharmaceutical Holdings Limited, Omeros Corporation, and KM Biologics Co Ltd.

North America was the largest region in the purpura treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in purpura treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the purpura treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The purpura treatment market consists of revenues earned by entities by providing services such as diagnostic evaluations, immunosuppressive therapy, intravenous immunoglobulin (IVIG) infusions, platelet transfusions, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The purpura treatment market also includes sales of products including corticosteroids, immunoglobulins (IVIG), biologics, immunosuppressants, and diagnostic kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Purpura Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on purpura treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for purpura treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The purpura treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Non-Thrombocytopenic Purpura; Thrombocytopenic Purpura; Allergic Purpura
• 2) By Treatment Type: Topical Treatments; Oral Medications; Intravitreal Injections; Laser Therapy; Photodynamic Therapy
• 3) By Cases: Acute; Chronic
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End-User: Hospitals; Clinics; Other End-Users
• Subsegments:
• 1) By Non-Thrombocytopenic Purpura: Idiopathic Purpura; Senile Purpura; Vascular Abnormalities
• 2) By Thrombocytopenic Purpura: Immune Thrombocytopenic Purpura (ITP); Drug-induced Thrombocytopenic Purpura; Secondary Thrombocytopenic Purpura
• 3) By Allergic Purpura: Drug-induced Allergic Purpura; Food-induced Allergic Purpura; Infectious-related Allergic Purpura
• Companies Mentioned: Merck & Co Inc.; Sanofi S.A.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Purpura Treatment Market Characteristics

3. Purpura Treatment Market Trends And Strategies

4. Purpura Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Purpura Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Purpura Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Purpura Treatment Market Growth Rate Analysis
• 5.4. Global Purpura Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Purpura Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Purpura Treatment Total Addressable Market (TAM)

6. Purpura Treatment Market Segmentation

• 6.1. Global Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Thrombocytopenic Purpura
• Thrombocytopenic Purpura
• Allergic Purpura
• 6.2. Global Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Treatments
• Oral Medications
• Intravitreal Injections
• Laser Therapy
• Photodynamic Therapy
• 6.3. Global Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute
• Chronic
• 6.4. Global Purpura Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Purpura Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End-Users
• 6.6. Global Purpura Treatment Market, Sub-Segmentation Of Non-Thrombocytopenic Purpura, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Idiopathic Purpura
• Senile Purpura
• Purpura Vascular Abnormalities
• 6.7. Global Purpura Treatment Market, Sub-Segmentation Of Thrombocytopenic Purpura, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Thrombocytopenic Purpura (ITP)
• Drug-induced Thrombocytopenic Purpura
• Secondary Thrombocytopenic Purpura
• 6.8. Global Purpura Treatment Market, Sub-Segmentation Of Allergic Purpura, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug-Induced Allergic Purpura
• Food-Induced Allergic Purpura
• Infectious-related Allergic Purpura

7. Purpura Treatment Market Regional And Country Analysis

• 7.1. Global Purpura Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Purpura Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Purpura Treatment Market

• 8.1. Asia-Pacific Purpura Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Purpura Treatment Market

• 9.1. China Purpura Treatment Market Overview
• 9.2. China Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Purpura Treatment Market

• 10.1. India Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Purpura Treatment Market

• 11.1. Japan Purpura Treatment Market Overview
• 11.2. Japan Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Purpura Treatment Market

• 12.1. Australia Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Purpura Treatment Market

• 13.1. Indonesia Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Purpura Treatment Market

• 14.1. South Korea Purpura Treatment Market Overview
• 14.2. South Korea Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Purpura Treatment Market

• 15.1. Western Europe Purpura Treatment Market Overview
• 15.2. Western Europe Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Purpura Treatment Market

• 16.1. UK Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Purpura Treatment Market

• 17.1. Germany Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Purpura Treatment Market

• 18.1. France Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Purpura Treatment Market

• 19.1. Italy Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Purpura Treatment Market

• 20.1. Spain Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Purpura Treatment Market

• 21.1. Eastern Europe Purpura Treatment Market Overview
• 21.2. Eastern Europe Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Purpura Treatment Market

• 22.1. Russia Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Purpura Treatment Market

• 23.1. North America Purpura Treatment Market Overview
• 23.2. North America Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Purpura Treatment Market

• 24.1. USA Purpura Treatment Market Overview
• 24.2. USA Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Purpura Treatment Market

• 25.1. Canada Purpura Treatment Market Overview
• 25.2. Canada Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Purpura Treatment Market

• 26.1. South America Purpura Treatment Market Overview
• 26.2. South America Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Purpura Treatment Market

• 27.1. Brazil Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Purpura Treatment Market

• 28.1. Middle East Purpura Treatment Market Overview
• 28.2. Middle East Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Purpura Treatment Market

• 29.1. Africa Purpura Treatment Market Overview
• 29.2. Africa Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Purpura Treatment Market Competitive Landscape And Company Profiles

• 30.1. Purpura Treatment Market Competitive Landscape
• 30.2. Purpura Treatment Market Company Profiles
  • 30.2.1. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Purpura Treatment Market Other Major And Innovative Companies

• 31.1. CSL Limited
• 31.2. Intas Pharmaceuticals Ltd.
• 31.3. Biogen Inc.
• 31.4. Chugai Pharmaceutical Co Ltd.
• 31.5. Sun Pharmaceutical Industries Limited
• 31.6. Octapharma AG
• 31.7. Grifols S.A.
• 31.8. GC Pharma
• 31.9. Emergent BioSolutions Inc.
• 31.10. Kissei Pharmaceutical Co Ltd.
• 31.11. Ablynx N.V.
• 31.12. Shire plc
• 31.13. Lee's Pharmaceutical Holdings Limited
• 31.14. Omeros Corporation
• 31.15. KM Biologics Co Ltd.

32. Global Purpura Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Purpura Treatment Market

34. Recent Developments In The Purpura Treatment Market

35. Purpura Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Purpura Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Purpura Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Purpura Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer